Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Conferone is a natural sesquiterpene coumarin isolated from the roots of *Ferula badrakema*. It is primarily recognized for its potent chemosensitizing activity rather than direct cytotoxicity. In preclinical studies involving bladder cancer cell lines (such as 5637 cells), conferone has been shown to significantly enhance the cytotoxic effects of vincristine. Its mechanism of action involves the inhibition of P-glycoprotein (P-gp), an ATP-binding cassette transporter that facilitates the efflux of various chemotherapeutic drugs, thereby contributing to multidrug resistance (MDR). By blocking P-gp, conferone increases the intracellular accumulation and efficacy of co-administered drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on conferone.